Skip to content

Trial Summary

This study aims to screen patients with advanced cancer and unmet clinical needs for actionable biomarkers to be used to guide therapy.

Acronym:

MoST

ACTRN/NCT /ethics:

ACTRN12616000908437

Scientific title:

The Cancer Molecular Screening and Therapeutics (MoST) Program – A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need.

Sponsor / Cooperative group:

The University of Sydney

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeEarly detection, diagnosis, prognosis
PhaseAll phases
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2016-09-09
Anticipated End Date2020-09-11

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruitment on Hold